Who is sponsoring NCT04818866?

NCT04818866 is sponsored by University of Michigan.

What condition does NCT04818866 study?

NCT04818866 studies Covid19, Outcome, Fatal, Respiratory Failure, Acute Kidney Injury, Inflammation.

Is NCT04818866 still recruiting?

NCT04818866 is currently completed. Last updated 31 October 2023.

Last reviewed 2023-10-31 · How we verify

NCT04818866: ISIC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

International Study of Inflammation in COVID-19

Completed Last updated 31 October 2023

What this trial tests

trial testing SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase in Covid19 in 4,463 participants. Completed in 1 December 2022.

Timeline

1 February 2020

Primary endpoint
1 December 2022

1 December 2022

Quick facts

Lead sponsor	University of Michigan
Status	Completed
Study type	OBSERVATIONAL
Enrollment	4,463
Start date	1 February 2020
Primary completion	1 December 2022
Estimated completion	1 December 2022
Sites	1 location across United States

Drugs / interventions tested

SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase

Conditions studied

Covid19 — all drugs for Covid19 →
Outcome, Fatal — all drugs for Outcome, Fatal →
Respiratory Failure — all drugs for Respiratory Failure →
Acute Kidney Injury — all drugs for Acute Kidney Injury →

Sponsor

University of Michigan

Who can join

18 and older, any sex, with Covid19 or Outcome, Fatal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective multi-center observational study which purpose is to evaluate the ability of blood-based inflammatory markers to risk-stratify patients hospitalized for Covid-19. Blood-based biomarkers examined include: soluble urokinase plasminogen activator receptor (suPAR), C-reactive protein (CRP), procalcitonin, D-dimer, ferritin, lactate dehydrogenase and interleukin-6.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19.
Vasbinder A, Anderson E, Shadid H, Berlin H, et al · · 2022 · cited 55× · PMID 35045184 · DOI 10.2337/dc21-2102
Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19.
Pan M, Vasbinder A, Anderson E, Catalan T, et al · · 2021 · cited 21× · PMID 34889102 · DOI 10.1161/jaha.121.023535
Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID-19.
Luo S, Vasbinder A, Du-Fay-de-Lavallaz JM, Gomez JMD, et al · · 2022 · cited 13× · PMID 35924778 · DOI 10.1161/jaha.122.025198
SuPAR, biomarkers of inflammation, and severe outcomes in patients hospitalized for COVID-19: The International Study of Inflammation in COVID-19.
Vasbinder A, Padalia K, Pizzo I, Machado K, et al · · 2024 · cited 10× · PMID 38235904 · DOI 10.1002/jmv.29389
Obesity, Inflammation, and Clinical Outcomes in COVID-19: A Multicenter Prospective Cohort Study.
Hutten CG, Padalia K, Vasbinder A, Huang Y, et al · · 2024 · cited 9× · PMID 38635301 · DOI 10.1210/clinem/dgae273

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other University of Michigan trials

Trials by the same sponsor.

NCT07536919 — Integrating Care for Hypertension-Diabetes MULTImorbidity in Guatemala Through HEARTS Implementation · NA · not yet recruiting
NCT05509842 — Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD) · NA · not yet recruiting
NCT06311188 — Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness · NA · not yet recruiting
NCT07471646 — Effects of Ramadan Fasting With Exercise on Cardiometabolic Health · NA · not yet recruiting
NCT06671925 — A Community Health Worker-Led Program for Chronic Pain and Loneliness in Older Adults · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04818866 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Michigan
Last refreshed: 31 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04818866.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing